Xeris Biopharma files New Jersey patent suits after KEVEYIS patent grant

Bitget2026/10/14 11:08

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Xeris Biopharma filed patent infringement suits on Oct. 13, 2026 in New Jersey federal court tied to KEVEYIS (dichlorphenamide).
Actions follow issuance of U.S. Patent No. 12,758,502 covering the product.
Claims target proposed generic dichlorphenamide products, alleging infringement through making, selling, or importing.
Relief sought includes an injunction, monetary damages, enhanced damages, attorneys’ fees, and costs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xeris Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001867096-26-000091), on October 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Xeris Biopharma files New Jersey patent suits after KEVEYIS patent grant

You may also like

Crypto prices